Spotlight On 3 TSX Penny Stocks With Market Caps Over CA$90M

In This Article:

The Canadian market has shown impressive growth, climbing 1.4% over the last week and 28% over the past year, with earnings expected to grow by 16% annually in the coming years. For investors willing to look beyond well-known companies, penny stocks—often representing smaller or newer enterprises—can present intriguing opportunities. Although 'penny stock' might seem like an outdated term, these investments remain relevant today as they can offer hidden value and potential for substantial returns when backed by strong financials.

Top 10 Penny Stocks In Canada

Name

Share Price

Market Cap

Financial Health Rating

PetroTal (TSX:TAL)

CA$0.68

CA$620.88M

★★★★★★

Findev (TSXV:FDI)

CA$0.41

CA$11.75M

★★★★★☆

Winshear Gold (TSXV:WINS)

CA$0.14

CA$4.4M

★★★★★★

Mandalay Resources (TSX:MND)

CA$3.16

CA$297.04M

★★★★★★

Pulse Seismic (TSX:PSD)

CA$2.35

CA$119.71M

★★★★★★

Amerigo Resources (TSX:ARG)

CA$1.83

CA$303.72M

★★★★★☆

Foraco International (TSX:FAR)

CA$2.25

CA$221.84M

★★★★★☆

East West Petroleum (TSXV:EW)

CA$0.035

CA$3.17M

★★★★★★

Newport Exploration (TSXV:NWX)

CA$0.115

CA$12.14M

★★★★★★

NamSys (TSXV:CTZ)

CA$1.15

CA$30.89M

★★★★★★

Click here to see the full list of 947 stocks from our TSX Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Satellos Bioscience

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Satellos Bioscience Inc. is a biotechnology company focused on developing regenerative therapeutics for degenerative muscle diseases, primarily operating in Canada and Australia, with a market cap of CA$90.52 million.

Operations: Currently, there are no reported revenue segments for the biotechnology company focused on regenerative therapeutics for muscle diseases.

Market Cap: CA$90.52M

Satellos Bioscience Inc., with a market cap of CA$90.52 million, is pre-revenue and currently in the early stages of clinical development for its drug SAT-3247 targeting Duchenne muscular dystrophy. Recent announcements highlight promising preclinical results and the commencement of Phase 1 trials, which are crucial steps for a biotech firm at this stage. Despite being unprofitable with increasing losses, Satellos has no debt and maintains sufficient short-term assets to cover liabilities. However, it faces challenges such as limited cash runway if expenses continue to grow at historical rates and an inexperienced management team.

TSX:MSCL Financial Position Analysis as at Oct 2024
TSX:MSCL Financial Position Analysis as at Oct 2024

Elemental Altus Royalties

Simply Wall St Financial Health Rating: ★★★★★★